Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer

Abstract Background Chimeric antigen receptor (CAR)‐engineered cell therapies have made significant progress in haematological cancer treatment. This success has motivated researchers to investigate its potential applications in non‐cancerous diseases, with substantial strides already made in this f...

Full description

Saved in:
Bibliographic Details
Main Authors: Lvying Wu, Lingfeng Zhu, Jin Chen
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/ctm2.70306
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Chimeric antigen receptor (CAR)‐engineered cell therapies have made significant progress in haematological cancer treatment. This success has motivated researchers to investigate its potential applications in non‐cancerous diseases, with substantial strides already made in this field. Main Body This review summarises the latest research on CAR‐engineered cell therapies, with a particular focus on CAR‐T cell therapy for non‐cancerous diseases, including but not limited to infectious diseases, autoimmune diseases, cardiac diseases and immune‐mediated disorders in transplantation. Additionally, the review discusses the current obstacles that need to be addressed for broader clinical applications. Conclusion With ongoing research and continuous improvements, CAR‐engineered cell therapy holds promise as a potent tool for treating various diseases in the future. Key points CAR‐engineered cell therapy has expanded beyond cancer to treat autoimmune diseases, infections, cardiac diseases, and transplant‐related rejection. The CAR platform is diverse, with various cell types such as CAR‐T, CAR‐NK, and CAR‐M potentially suited for different disease contexts. The safety, efficacy, and practicality of CAR cell therapy in non‐cancer diseases remain challenging, requiring further technological optimization and clinical translation.
ISSN:2001-1326